Tardive dyskinesia

Current Treatment Options in Neurology

Volumn 13, Issue 3, 2011, Pages 231-241

  Aia, Pratibha G ^a   Revuelta, Gonzalo J ^b   Cloud, Leslie J ^a   Factor, Stewart A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; AMANTADINE; ANTIOXIDANT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; CENTRAL DEPRESSANT AGENT; CLONAZEPAM; CLOZAPINE; DIHYDROTETRABENAZINE; DRONEDARONE; ETIRACETAM; METHYLDOPA; METIROSINE; MINERAL OIL; NEUROLEPTIC AGENT; PHENOBARBITAL; PLACEBO; PROPANOL; QUETIAPINE; RESERPINE; TETRABENAZINE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT;

AGRANULOCYTOSIS; AKATHISIA; ANKLE EDEMA; APATHY; ARTICLE; ATAXIA; ATRIOVENTRICULAR BLOCK; BEDTIME DOSAGE; BEHAVIOR DISORDER; BRADYCARDIA; BRAIN DEPTH STIMULATION; CHOREA; CLINICAL EFFECTIVENESS; CONFUSION; CONGESTIVE HEART FAILURE; DEPRESSION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; DYSKINESIA; DYSPHAGIA; DYSTONIA; EPILEPSY; FATIGUE; FLATULENCE; HEART ARRHYTHMIA; HEART BLOCK; HUMAN; HYPERKINESIA; HYPOTENSION; INSOMNIA; LETHARGY; LIMB DISEASE; LIVEDO RETICULARIS; LOW DRUG DOSE; MOTOR DYSFUNCTION; MYOCARDITIS; NAUSEA; NIGHTMARE; NONHUMAN; OROFACIAL DYSKINESIA; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; PARADOXICAL DRUG REACTION; PARKINSONISM; PSYCHOSIS; QT INTERVAL; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SPEECH DISORDER; SUICIDAL IDEATION; TARDIVE DYSKINESIA; THROMBOCYTE AGGREGATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEAKNESS; XEROSTOMIA;

EID: 79955869156     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-011-0117-x     Document Type: Article

References (40)

1. W Kruse 1960 Persistent muscular restlessness after phenothiazine treatment: report of 3 cases Am J Psychiatry 117 152 153 14412282 1:STN:280:DyaF3c7msV2gtg%3D%3D
2. CU Correll EM Schenk 2008 Tardive dyskinesia and new antipsychotics Curr Opin Psychiatry 21 2 151 156 18332662 10.1097/YCO.0b013e3282f53132 (Pubitemid 351339869)
3. A Rapaport, et al. 2000 Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia Mov Disord 15 2 352 355 10752596 10.1002/1531-8257(200003)15:2<352::AID-MDS1030>3.0.CO;2-X 1:STN:280:DC%2BD3c3hsValsw%3D%3D (Pubitemid 30166753)
4. DN Bateman MD Rawlins JM Simpson 1985 Extrapyramidal reactions with metoclopramide Br Med J (Clin Res Ed) 291 6500 930 932 10.1136/bmj.291.6500.930 1:STN:280:DyaL28%2FgtFCnuw%3D%3D (Pubitemid 16236563)
5. BE Wiholm, et al. 1984 Tardive dyskinesia associated with metoclopramide Br Med J (Clin Res Ed) 288 6416 545 547 10.1136/bmj.288.6416.545 1:STN:280:DyaL2c7ivFaktw%3D%3D (Pubitemid 14117374)
6. DV Jeste RJ Wyatt 1982 Therapeutic strategies against tardive dyskinesia. Two decades of experience Arch Gen Psychiatry 39 7 803 816 6131655 1:STN:280:DyaL3s7lt1WjtA%3D%3D (Pubitemid 12090304)
7. JM Kane M Woerner J Lieberman 1988 Tardive dyskinesia: prevalence, incidence, and risk factors J Clin Psychopharmacol 8 4 Suppl 52S 56S 3065365 1:STN:280:DyaL1M7itl2gsQ%3D%3D
8. Marsden CD, MRHS, Baldessarini RJ. Extrapyramidal movement disorders produced by antipsychotic drugs. In: Hirsch SR, Bradley PB, editors. Pharmacology and Treatment of Schizophrenia. London: Oxford; 1986.
9. MG Woerner, et al. 1993 Diabetes and development of tardive dyskinesia Am J Psychiatry 150 6 966 968 8098587 1:STN:280:DyaK3s3mtlamtw%3D%3D (Pubitemid 23156783)
10. R Yassa DV Jeste 1992 Gender differences in tardive dyskinesia: a critical review of the literature Schizophr Bull 18 4 701 715 1359633 1:STN:280:DyaK3s%2FmvVSltA%3D%3D
11. PM FitzGerald J Jankovic 1989 Tardive oculogyric crises Neurology 39 11 1434 1437 2573005 1:STN:280:DyaK3c%2FksVOgtg%3D%3D (Pubitemid 19285996)
12. Fahn S, Jankovic J. Principles and practice of movement disorders. Philadelphia: Churchill Livingstone; 2007.
13. AE Lang 1990 Clinical differences between metoclopramide- and antipsychotic-induced tardive dyskinesias Can J Neurol Sci 17 2 137 139 1972649 1:STN:280:DyaK3c3ptFegtg%3D%3D (Pubitemid 20177526)
14. MR Samie MA Dannenhoffer S Rozek 1987 Life-threatening tardive dyskinesia caused by metoclopramide Mov Disord 2 2 125 129 3504264 10.1002/mds.870020207 1:STN:280:DyaL1M%2Fls12rsQ%3D%3D
15. J Horiguchi, et al. 1999 Antipsychotic-induced life-threatening 'esophageal dyskinesia' Int Clin Psychopharmacol 14 2 123 127 10220128 10.1097/00004850-199903000-00010 1:STN:280:DyaK1M3jsFGgtg%3D%3D
16. LA Labbate, et al. 1997 Tardive dyskinesia in older out-patients: a follow-up study Acta Psychiatr Scand 96 3 195 198 9296550 10.1111/j.1600-0447. 1997.tb10151.x 1:STN:280:DyaK2svktFWisA%3D%3D (Pubitemid 27368458)
17. A Fasano AR Bentivoglio 2009 Tetrabenazine Expert Opin Pharmacother 10 17 2883 96 19929707 10.1517/14656560903386292 1:CAS:528:DC%2BD1MXhsVyjurzO This is the latest review on the use of tetrabenazine in hyperkinetic movement disorders.
18. Huntington Study Group 2006 Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial Neurology 66 3 366 372 10.1212/01.wnl.0000198586.85250.13 (Pubitemid 43739938)
19. WG Ondo PA Hanna J Jankovic 1999 Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol Am J Psychiatry 156 8 1279 1281 10450276 1:STN:280:DyaK1MznvVOksg%3D%3D (Pubitemid 29374894)
20. C Kenney C Hunter J Jankovic 2007 Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders Mov Disord 22 2 193 197 17133512 10.1002/mds.21222 (Pubitemid 46374760)
21. CC Huang, et al. 1980 Evaluation of reserpine and alpha-methyldopa in the treatment of tardive dyskinesia Psychopharmacol Bull 16 3 41 43 7403399 1:STN:280:DyaL3c3lslagsg%3D%3D
22. CC Huang, et al. 1981 Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia Psychopharmacology (Berl) 73 4 359 362 10.1007/BF00426466 1:STN:280:DyaL3M3kslygtw%3D%3D (Pubitemid 11114122)
23. S Fahn 1985 A therapeutic approach to tardive dyskinesia J Clin Psychiatry 46 4 Pt 2 19 24 2858474 1:STN:280:DyaL2M7lslCrsg%3D%3D (Pubitemid 15096644)
24. JA Lieberman, et al. 1991 The effects of clozapine on tardive dyskinesia Br J Psychiatry 158 503 510 1675900 10.1192/bjp.158.4.503 1:STN:280: DyaK3M3nsVOlsg%3D%3D
25. NA Bacher HA Lewis 1983 Propranolol, anxiety, and tardive dyskinesia J Clin Psychiatry 44 5 196 6133849 1:STN:280:DyaL3s3htlWqtQ%3D%3D (Pubitemid 13082965)
26. A Perenyi A Farkas 1983 Propranolol in the treatment of tardive-dyskinesia Biol Psychiatry 18 3 391 394 6132627 1:STN:280: DyaL3s7nvFWjug%3D%3D
27. FN Pitts 1982 Treatment of tardive-dyskinesia with propranolol J Clin Psychiatry 43 8 304 304 7096269
28. GR Schrodt, et al. 1982 Treatment of tardive-dyskinesia with propranolol J Clin Psychiatry 43 8 328 331 6124534
29. Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2000;(2):CD000209.
30. LA Adler, et al. 1993 Vitamin E treatment of tardive dyskinesia Am J Psychiatry 150 9 1405 1407 8102511 1:STN:280:DyaK3szls1anuw%3D%3D (Pubitemid 23259578)
31. LA Adler, et al. 1999 Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group Arch Gen Psychiatry 56 9 836 841 12892048 10.1001/archpsyc.56.9.836 1:CAS:528:DyaK1MXmt1WlsLY%3D (Pubitemid 29420705)
32. GK Thaker, et al. 1990 Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy Am J Psychiatry 147 4 445 451 1969244 1:STN:280:DyaK3c7ps1ektg%3D%3D (Pubitemid 20107108)
33. A Bobruff, et al. 1981 Clonazepam and phenobarbital in tardive dyskinesia Am J Psychiatry 138 2 189 193 6109454 1:STN:280:DyaL3M7gs12qtQ%3D%3D (Pubitemid 11170265)
34. S Pappa, et al. 2010 Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study Clin Neuropharmacol 33 6 271 275 21121175 10.1097/WNF.0b013e3181ffde32 1:CAS:528:DC%2BC3cXhsVahu7fM This is one of the latest small trials using amantadine in the treatment of TD.
35. S Angus, et al. 1997 A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia J Clin Psychopharmacol 17 2 88 91 10950469 10.1097/00004714-199704000-00004 1:STN:280:DC%2BD3cvitFWltA%3D%3D (Pubitemid 27148302)
36. SW Woods, et al. 2008 Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study J Clin Psychiatry 69 4 546 554 18312060 10.4088/JCP.v69n0405 1:CAS:528:DC%2BD1cXmtFShsbg%3D (Pubitemid 351792328)
37. CW Slotema, et al. 2008 Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study Prog Neuropsychopharmacol Biol Psychiatry 32 2 507 509 18022743 10.1016/j.pnpbp.2007.10.004 1:CAS:528:DC%2BD1cXhsVKiur8%3D (Pubitemid 351178970)
38. CD Esper A Freeman SA Factor 2010 Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy Parkinsonism Relat Disord 16 7 438 441 20494607 10.1016/j.parkreldis.2010.04.007
39. JM Hennings KE Bötzel TC Wetter 2008 Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature Prog Neuropsychopharmacol Biol Psychiatry 32 5 1167 1171 17936461 10.1016/j.pnpbp.2007.09.010 1:CAS:528:DC%2BD1cXnsF2lur4%3D
40. ML Welter D Grabli M Vidailhet 2010 Deep brain stimulation for hyperkinetics disorders: dystonia, tardive dyskinesia, and tics Curr Opin Neurol 23 4 420 425 20610993